ARTV Artiva Biotherapeutics, Inc.
-
Artiva Biotherapeutics Missed Consensus Estimates
Monday, November 9, 2026 · 12:00 AM ET
Artiva Biotherapeutics (ARTV) reported a loss of $0.56 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.54 per share. The company missed consensus estimates by 3.70%.
Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.56)
Earnings Whisper®
—
Consensus Estimate
($0.54)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—